Clinical Information in Relation to Cyclin E and p27
| (A) . | Cyclin E ≤2% . | Cyclin E >2% . | P Value . |
|---|---|---|---|
| Age (yr) | 61 | 64 | .29 |
| LDH (μkat/L) | 6.5 | 7.7 | .05 |
| S-phase fraction (%) | 1.7 | 5.4 | <.001 |
| p27 (%) | 44 | 31 | .05 |
| Indolent/aggressive | 24/5 | 21/48 | <.001 |
| Stage I/II/III/IV | 4/2/5/18 | 15/13/11/30 | .26 |
| General symptom A/B | 22/7 | 45/23 | .24 |
| Male/female | 24/5 | 38/31 | .008 |
| n | 29 | 69 | |
| (B) | p27 ≤15% | p27 >15% | P Value |
| Age (yr) | 72 | 61 | .008 |
| LDH (μkat/L) | 9.0 | 7.0 | .004 |
| S-phase fraction (%) | 12.7 | 2.8 | .001 |
| Cyclin E (%) | 6.8 | 5.0 | .09 |
| Indolent/aggressive | 6/17 | 40/37 | .02 |
| Stage I/II/III/IV | 3/3/5/12 | 21/12/10/37 | .58 |
| General symptom A/B | 13/9 | 55/22 | .20 |
| Male/female | 15/8 | 49/28 | .55 |
| n | 23 | 77 |
| (A) . | Cyclin E ≤2% . | Cyclin E >2% . | P Value . |
|---|---|---|---|
| Age (yr) | 61 | 64 | .29 |
| LDH (μkat/L) | 6.5 | 7.7 | .05 |
| S-phase fraction (%) | 1.7 | 5.4 | <.001 |
| p27 (%) | 44 | 31 | .05 |
| Indolent/aggressive | 24/5 | 21/48 | <.001 |
| Stage I/II/III/IV | 4/2/5/18 | 15/13/11/30 | .26 |
| General symptom A/B | 22/7 | 45/23 | .24 |
| Male/female | 24/5 | 38/31 | .008 |
| n | 29 | 69 | |
| (B) | p27 ≤15% | p27 >15% | P Value |
| Age (yr) | 72 | 61 | .008 |
| LDH (μkat/L) | 9.0 | 7.0 | .004 |
| S-phase fraction (%) | 12.7 | 2.8 | .001 |
| Cyclin E (%) | 6.8 | 5.0 | .09 |
| Indolent/aggressive | 6/17 | 40/37 | .02 |
| Stage I/II/III/IV | 3/3/5/12 | 21/12/10/37 | .58 |
| General symptom A/B | 13/9 | 55/22 | .20 |
| Male/female | 15/8 | 49/28 | .55 |
| n | 23 | 77 |
Median values and number of cases are noted. Differences are calculated with Mann-Whitney's test and χ2-test.